# Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

> **NCT01383759** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Light Chain Deposition Disease (LCDD or MIDD)
- Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)
- Monoclonal Immunoglobulin Deposition Disease (MIDD)
- Amyloidosis

## Interventions

- **DRUG:** Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone

## Key facts

- **NCT ID:** NCT01383759
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-24
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01383759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01383759, "Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01383759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*